Showing results (141-150 of 154) with videos related to

Sort By:
Pageof 16
The Lancet. Haematology|June 27, 2020
Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trialElias Jabbour, Guillaume Richard-Carpentier, Yuya Sasaki, et al.
American Journal of Hematology|December 2, 2020
Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortalityAbhishek Maiti, Wei Qiao, Koji Sasaki, et al.
Blood Cancer Discovery|July 3, 2025
Multimodal and Data-Driven Assessment of Myeloid Neoplasms Refines Classification across Disease StatesCurtis A Lachowiez, Georgios Asimomitis, Elsa Bernard, et al.
Blood Advances|April 1, 2021
Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemiaAbhishek Maiti, Courtney D DiNardo, Sa A Wang, et al.
Blood Advances|July 11, 2025
Landscape and clinicopathologic features of RAS pathway mutations in chronic myelomonocytic leukemiaGuillermo Montalban-Bravo, Sanam Loghavi, Ziyi Li, et al.
Cancer|November 25, 2024
Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemiaWei-Ying Jen, Jennifer Marvin-Peek, Hagop M Kantarjian, et al.
The Lancet. Oncology|October 3, 2024
Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trialEunice S Wang, Ghayas C Issa, Harry P Erba, et al.
Leukemia|February 25, 2025
Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemiaCourtney D DiNardo, Wei-Ying Jen, Koichi Takahashi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 25, 2025
Ziftomenib in Relapsed or Refractory NPM1-Mutated AMLEunice S Wang, Pau Montesinos, James Foran, et al.
Blood|June 2, 2026
Ziftomenib with venetoclax and azacitidine in relapsed/refractory NPM1-mutated acute myeloid leukemiaEunice S Wang, Harry P Erba, Amer M Zeidan, et al.
Pageof 16